Close
Company Search
Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Glaxosmithkline (GSK) Share Price

Price 1,919.50p on 24-07-2026 at 15:40:00
Change 14.00p 0.73%
Buy 1,926.00p
Sell 1,925.00p
Add to Watchlist
Add to Portfolio
Add to Quickpicks
Last Trade: Sell 1,123.00 at 1,919.50p
Day's Volume: 5,768,913
Last Close: 1,919.50p
Open: 1,893.00p
ISIN: GB00BN7SWP63
Day's Range 1,893.00p - 1,933.50p
52wk Range: 1,361.00p - 2,282.00p
Market Capitalisation: £76.89b
VWAP: 1,919.1018p
Shares in Issue: 4.01b

Sector: Medicine and Biotech

Listed In: FTSE All-Share, FTSE All-Share ex Investment Trusts, FTSE Higher Yield, FTSE 350 ex Investment Trusts, FTSE 350 , FTSE 100,

Glaxosmithkline (GSK) Latest Trades

Buy/Sell Volume Trade Prc Trade Type Trade Time
Sell* 1,123 1,919.50p SI Trade
 16:35:25 - 24-Jul-26
Sell* 2,420 1,919.50p SI Trade
 16:35:25 - 24-Jul-26
Sell* 116 1,919.50p SI Trade
 16:35:25 - 24-Jul-26
Sell* 7,462 1,919.50p Automatic Execution
 16:35:25 - 24-Jul-26
Sell* 8,162 1,919.50p Automatic Execution
 16:35:25 - 24-Jul-26
Sell* 200 1,919.50p Automatic Execution
 16:35:25 - 24-Jul-26
Sell* 200 1,919.50p Automatic Execution
 16:35:25 - 24-Jul-26
Sell* 200 1,919.50p Automatic Execution
 16:35:25 - 24-Jul-26
Sell* 200 1,919.50p Automatic Execution
 16:35:25 - 24-Jul-26
Sell* 200 1,919.50p Automatic Execution
 16:35:25 - 24-Jul-26
See more Glaxosmithkline trades

Glaxosmithkline (GSK) Share Price History

Time period:
to
Date Open High Low Close Volume
23rd Jul 2026 (Thu) 1,894.50 1,905.50 1,866.00 1,905.50 8,013,378
22nd Jul 2026 (Wed) 1,887.00 1,936.50 1,882.00 1,910.50 4,480,225
21st Jul 2026 (Tue) 1,858.00 1,913.00 1,851.50 1,893.00 19,807,282
20th Jul 2026 (Mon) 1,909.00 1,920.00 1,881.00 1,882.00 9,594,138
17th Jul 2026 (Fri) 1,966.00 1,982.00 1,868.00 1,916.50 13,825,247
16th Jul 2026 (Thu) 1,904.00 1,958.00 1,896.00 1,956.00 5,092,934
15th Jul 2026 (Wed) 1,920.50 1,929.00 1,903.50 1,916.50 8,355,831
14th Jul 2026 (Tue) 1,956.00 1,957.50 1,905.00 1,920.50 4,279,605
13th Jul 2026 (Mon) 1,960.00 1,983.50 1,934.00 1,953.50 4,209,058
10th Jul 2026 (Fri) 1,963.50 1,981.00 1,954.00 1,961.50 6,365,614
9th Jul 2026 (Thu) 1,960.00 1,982.50 1,951.00 1,959.50 5,592,231
8th Jul 2026 (Wed) 1,990.50 1,990.50 1,964.00 1,979.50 4,243,160
7th Jul 2026 (Tue) 1,998.00 2,031.00 1,982.00 2,003.00 4,183,205
6th Jul 2026 (Mon) 2,025.00 2,048.00 1,967.50 1,983.00 15,157,640
3rd Jul 2026 (Fri) 2,005.00 2,015.00 1,988.00 2,015.00 2,548,103
2nd Jul 2026 (Thu) 1,949.00 2,014.00 1,943.00 2,004.00 17,566,583
1st Jul 2026 (Wed) 1,981.00 1,992.00 1,930.00 1,930.00 8,817,916
30th Jun 2026 (Tue) 1,999.50 2,009.00 1,946.50 1,981.00 13,957,667
29th Jun 2026 (Mon) 1,995.00 1,996.50 1,969.00 1,979.50 9,717,943
26th Jun 2026 (Fri) 1,972.50 1,995.50 1,945.50 1,983.00 13,837,274
25th Jun 2026 (Thu) 1,949.00 1,991.00 1,926.50 1,983.50 8,999,065
24th Jun 2026 (Wed) 1,967.00 1,984.00 1,950.00 1,950.00 5,923,852
See more Glaxosmithkline price history

Glaxosmithkline (GSK) Regulatory News

Date Source Headline
22nd Jul 2026 5:22 pm RNS Jideytro approved in US for certain lung cancers
20th Jul 2026 7:00 am RNS Bexsero 1-dose booster EMA file acceptance
17th Jul 2026 12:00 pm RNS Audit tender conclusion
17th Jul 2026 9:30 am RNS Camlipixant phase III results update
16th Jul 2026 3:30 pm RNS Director/PDMR Shareholding
15th Jul 2026 1:38 pm RNS GSK completes acquisition of Nuvalent, Inc
14th Jul 2026 3:30 pm RNS Director/PDMR Shareholding
13th Jul 2026 3:30 pm RNS Director/PDMR Shareholding
13th Jul 2026 7:00 am RNS Positive Jemperli data in dMMR/MSI-H rectal cancer
10th Jul 2026 11:58 am RNS Hansoh positive Phase III results for Riz-Rez
See more Glaxosmithkline regulatory news

Glaxosmithkline (GSK) Share News

LONDON BROKER RATINGS: UBS cuts Standard Chartered; Shore ups HSBC

24th Jul 2026 09:14

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning and on Thursday: Read More

GSK hails first lung cancer medicine approval as US FDA backs Jideytro

22nd Jul 2026 19:36

(Alliance News) - GSK PLC on Wednesday said that the US Food & Drug Administration has approved zidesamtinib, branded as Jideytro, for previously treated ROS1-positive non-small cell lung cancer. Read More

UK earnings, trading statements calendar - next 7 days

21st Jul 2026 13:36

Read More

IN BRIEF: GSK secures European review for meningitis vaccine booster

20th Jul 2026 10:35

GSK PLC - London-based pharmaceutical maker - The European Medicines Agency accepts GSK's submission to update the label for Bexsero to include a single-dose booster for people aged 10 and older who previously had the vaccination against Meningitis B. "If adopted, a booster could help reduce the overall burden of invasive meningococcal disease in countries with established infant MenB programmes," GSK says. It says the submission is supported by a phase 3b, open-label, multi-centre study in 10- to 20-year-old patients, showing that a single dose was effective in boosting the immune responses of those vaccinated as infants. Invasive meningococcal disease is a rare disease caused by Neisseria meningitidis that can progress rapidly and has a fatality rate of 4% to 20%, GSK notes. Read More

LONDON BRIEFING: ProLogis announces fresh bid for Segro

20th Jul 2026 08:00

(Alliance News) - The FTSE 100 was called to open lower on Monday, after the US and Iran exchanged further strikes and as Andy Burnham prepares to officially succeed Keir Starmer as prime minister. Read More

See more Glaxosmithkline news
FTSE 100 Latest
Value10,736.23
Change97.06

Login to your account

Forgot Password?

Not Registered